 |
인쇄하기
취소
|
Pfizer to expand portfolio of generic medicines in Korea
Pfizer Korea is considering marketing medicines that are no longer patent protected, under its Established Products Business Unit strategy.
To this end, the company received Friday the approval of gemcitabine 200 mg and 1000 mg from the Food and Drug Administration.
“We will dramatically change Pfizer’s Established Products portfolio to an engine of positive growth,” a Pfizer Korea offici...
To this end, the company received Friday the approval of gemcitabine 200 mg and 1000 mg from the Food and Drug Administration.
“We will dramatically change Pfizer’s Established Products portfolio to an engine of positive growth,” a Pfizer Korea offici...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.